US/UK/Canada

Share

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.

Pick a time period -
Tags ( Active)

Interim Report, January-September 2014

January-September 2014 · Net sales reached SEK 10,198 million (9,664), corresponding to an increase of 6% and an organic growth[1] of 3% compared to previous year. · EBITDA amounted to SEK 2,978 million (2,719), corresponding to a 29.2% margin (28.1). · Operating profit amounted to SEK 1,283 million (1,087). · Profit after tax amounted to SEK 677 million (547). · Earnings per share reached SEK 2.24 (1.82). · Cash earnings per share amounted to SEK 6.34 (6.48). · Forecast for full-year 2014 “Meda expect sales for full-year 2014 to reach SEK 15 billion and that the

Meda AB (publ) – Interim report, January–September 2012

· Group net sales reached SEK 9,796 million (9,400). At fixed currency rates, sales increased 5%. · EBITDA amounted to SEK 3,043 million (3,493), corresponding to a 31.1% margin (37.2). · Operating profit amounted to SEK 1,442 million (1,986).   · Profit after tax totaled SEK 823 million (1,098). · Earnings per share reached SEK 2.79 (3.65). · Cash earnings per share reached SEK 6.18 (7.13). · Forecast for full-year 2012: “The Meda Group expects to achieve sales close to SEK 13,000 million and an EBITDA margin of around 30 percent.”CEO STATEMENT Organic

Meda AB (publ) – Interim report, January-September 2011

· Group net sales reached SEK 9,400 million (8,561). At fixed currency rates, sales increased 19%. · EBITDA rose to SEK 3,493 million (3,057[1]), corresponding to a 37.2% margin (35.7[1]). At fixed currency rates, EBITDA increased 24%[1]. · Operating profit amounted to SEK 1,986 million (1,772[1]).     · Profit after tax totaled SEK 1,098 million (1,249). Excluding non-recurring effects, profit after tax totaled SEK 1,098 million (940[2]).   · Earnings per share reached SEK 3.63 (4.13). Excluding non-recurring effects, earnings per share totaled SEK 3.63 (3.11[2]).

Meda AB (publ) – Interim report, January–September 2010

· Group sales reached SEK 8,561 million (9,918). Currency effects and increased competition for the Astelin and Optivar products are the most important reasons for lower sales compared to last year.  · EBITDA amounted to SEK 3,486 million (3,356), corresponding to a 40.7% margin (33.8).   · EBITDA, excluding a non-recurring effect[1] and currency fluctuations, declined by 1% to SEK 3,327 million (3,356), thus yielding a 35.9% margin (33.8).  · Operating profit amounted to SEK 2,201 million (2,275).  · Profit after tax totaled SEK 1,249 million (1,205).  · Earnings

There are no items matching the current filter
There are no more items matching the current filter
Back to top